iOnctura's Precision Cancer Treatments Gain Momentum
June 25, 2024, 3:35 am
iOnctura, a clinical-stage biopharmaceutical company based in Amsterdam, recently secured EUR80 million in Series B financing to accelerate the development of their lead asset, roginolisib, for the treatment of uveal melanoma and other oncology indications. The funding round, led by Syncona and the European Innovation Council Fund, showcases the growing interest in iOnctura's innovative approach to combat neglected and hard-to-treat cancers.
CEO Catherine Pickering expressed her excitement about the financing, highlighting the potential of iOnctura's precision oral small molecules to significantly impact the healthspan of patients with hard-to-treat cancers. With two therapeutic candidates already in mid-stage clinical development, iOnctura is poised to make a meaningful difference in the field of oncology.
Roginolisib, iOnctura's lead asset, is an allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. This novel approach targets cancers in ways that have not been explored before, offering new hope for patients with immune-mediated resistance and high expression of PI3Kδ in cancer cells.
The successful Phase Ib clinical trial results of roginolisib in uveal melanoma, a rare and challenging cancer of the eye, have paved the way for further expansion into other indications. With plans to initiate trials in non-small cell lung cancer and primary myelofibrosis later this year, iOnctura is committed to advancing their pipeline and bringing innovative treatments to patients in need.
In addition to roginolisib, iOnctura is also developing cambritaxestat, the only autotaxin inhibitor in clinical development for cancer treatment. With promising potency and specificity, cambritaxestat shows potential for treating highly fibrotic tumors that overexpress autotaxin, such as metastatic pancreatic cancer.
The support from new investors like Syncona and the EIC Fund, along with existing investors, underscores the confidence in iOnctura's approach to precision cancer treatments. The company's commitment to maximizing clinical impact and addressing neglected cancer types has positioned them as a key player in the fight against challenging cancers.
As iOnctura continues to advance their innovative therapies and expand into new indications, the future looks bright for patients in need of effective and targeted cancer treatments. With a strong focus on precision and clinical impact, iOnctura is paving the way for a new era in cancer treatment.
CEO Catherine Pickering expressed her excitement about the financing, highlighting the potential of iOnctura's precision oral small molecules to significantly impact the healthspan of patients with hard-to-treat cancers. With two therapeutic candidates already in mid-stage clinical development, iOnctura is poised to make a meaningful difference in the field of oncology.
Roginolisib, iOnctura's lead asset, is an allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. This novel approach targets cancers in ways that have not been explored before, offering new hope for patients with immune-mediated resistance and high expression of PI3Kδ in cancer cells.
The successful Phase Ib clinical trial results of roginolisib in uveal melanoma, a rare and challenging cancer of the eye, have paved the way for further expansion into other indications. With plans to initiate trials in non-small cell lung cancer and primary myelofibrosis later this year, iOnctura is committed to advancing their pipeline and bringing innovative treatments to patients in need.
In addition to roginolisib, iOnctura is also developing cambritaxestat, the only autotaxin inhibitor in clinical development for cancer treatment. With promising potency and specificity, cambritaxestat shows potential for treating highly fibrotic tumors that overexpress autotaxin, such as metastatic pancreatic cancer.
The support from new investors like Syncona and the EIC Fund, along with existing investors, underscores the confidence in iOnctura's approach to precision cancer treatments. The company's commitment to maximizing clinical impact and addressing neglected cancer types has positioned them as a key player in the fight against challenging cancers.
As iOnctura continues to advance their innovative therapies and expand into new indications, the future looks bright for patients in need of effective and targeted cancer treatments. With a strong focus on precision and clinical impact, iOnctura is paving the way for a new era in cancer treatment.